II Ivivi Technologies, Inc.

Ivivi Technologies, Inc. (AMEX:II), a leader in non-invasive, electrotherapeutic technologies, today announced that preliminary data from a randomized double-blind, placebo-controlled clinical study entitled �Effect of Pulsed Electromagnetic Fields (�PEMF�) on Post-Surgical Pain Reduction for Breast Augmentation� showed an 80% acceleration in pain relief in patients treated with the active technology as compared to patients treated with placebo units. The study was conducted at Akademikliniken Hospital in Stockholm, Sweden by Dr. Per Heden, an internationally-recognized plastic surgeon and researcher, to quantify the effect of Ivivi�s non-invasive PEMF technology on the reduction of pain in post-operative breast augmentation patients. Patients in the study were randomly assigned to either active or placebo treatment with the wearable, lightweight, disposable Ivivi units, and assessed for post-operative pain twice daily for several days after surgery. The preliminary data was presented at the Akademikliniken�s International Aesthetic Symposium that was held May 17-19, 2007 at the Grand H�tel in Stockholm, Sweden. The presentation, entitled �New Methods to Reduce Pain and Postoperative Discomfort� was delivered by Dr. Patrick Maxwell, an internationally-recognized plastic surgeon who currently serves as the chair of the Allergan Academy�. Allergan, Inc. has an exclusive worldwide distribution agreement to market, sell and distribute certain of Ivivi�s products in the aesthetic and bariatric medical procedure markets. �This study is the first to clinically confirm what plastic surgeons have seen anecdotally, that Ivivi�s PEMF therapy is an effective tool in reducing post-surgical pain,� commented Dr. Per Heden, of the Department of Plastic Surgery at Akademikliniken Hospital in Stockholm, and lead investigator on the study. �This study reinforces our clinical data that shows the ability of our technology to enhance post-surgical pain management. Since the publication of the American Heart Association Guidelines urging restricted use of non-steroidal anti-inflammatory drugs (NSAIDs), the need for non-pharmacological pain control has become critical for a large population of patients,� commented Andr� DiMino, Co-CEO, Ivivi Technologies. About the Study In the study, pain was measured twice daily beginning three to five hours after breast augmentation surgery, and continuing for eight days. In the two main arms of the study (15 patients each) one group of patients wore active units that delivered PEMF therapy on both breasts for 30 minutes on a regular basis for the duration of the study. The second had placebo units on each breast. For the data analysis, the cumulative, daily pain measurements were plotted for each group, and the slope of the group receiving treatment was compared to that of the placebo group. Mean daily cumulative pain measurements in patients receiving therapy decreased approximately 80% faster than those in the placebo group (p